SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype
- PMID: 33414384
- PMCID: PMC7790351
- DOI: 10.1038/s41419-020-03333-9
SARS-CoV-2 infection is associated with a pro-thrombotic platelet phenotype
Abstract
Novel coronavirus disease 2019 (COVID-19) is associated with a hypercoagulable state, characterized by abnormal coagulation parameters and by increased incidence of cardiovascular complications. With this study, we aimed to investigate the activation state and the expression of transmembrane proteins in platelets of hospitalized COVID-19 patients. We investigated transmembrane proteins expression with a customized mass cytometry panel of 21 antibodies. Platelets of 8 hospitalized COVID-19 patients not requiring intensive care support and without pre-existing conditions were compared to platelets of healthy controls (11 donors) with and without in vitro stimulation with thrombin receptor-activating peptide (TRAP). Mass cytometry of non-stimulated platelets detected an increased surface expression of activation markers P-Selectin (0.67 vs. 1.87 median signal intensity for controls vs. patients, p = 0.0015) and LAMP-3 (CD63, 0.37 vs. 0.81, p = 0.0004), the GPIIb/IIIa complex (4.58 vs. 5.03, p < 0.0001) and other adhesion molecules involved in platelet activation and platelet-leukocyte interactions. Upon TRAP stimulation, mass cytometry detected a higher expression of P-selectin in COVID-19 samples compared to controls (p < 0.0001). However, we observed a significantly reduced capacity of COVID-19 platelets to increase the expression of activation markers LAMP-3 and P-Selectin upon stimulation with TRAP. We detected a hyperactivated phenotype in platelets during SARS-CoV-2 infection, consisting of highly expressed platelet activation markers, which might contribute to the hypercoagulopathy observed in COVID-19. In addition, several transmembrane proteins were more highly expressed compared to healthy controls. These findings support research projects investigating antithrombotic and antiplatelet treatment regimes in COVID-19 patients, and provide new insights on the phenotypical platelet expression during SARS-CoV-2 infection.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Glycoprotein IIb/IIIa inhibition attenuates platelet-activating factor-induced platelet activation by reducing protein kinase C activity.J Thromb Haemost. 2003 Aug;1(8):1805-12. doi: 10.1046/j.1538-7836.2003.00324.x. J Thromb Haemost. 2003. PMID: 12911597
-
Platelet Surface Protein Expression and Reactivity upon TRAP Stimulation after BNT162b2 Vaccination.Thromb Haemost. 2022 Oct;122(10):1706-1711. doi: 10.1055/s-0041-1733934. Epub 2021 Aug 13. Thromb Haemost. 2022. PMID: 34388849
-
Platelet gene expression and function in patients with COVID-19.Blood. 2020 Sep 10;136(11):1317-1329. doi: 10.1182/blood.2020007214. Blood. 2020. PMID: 32573711 Free PMC article.
-
Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets?J Thromb Haemost. 2021 Jan;19(1):46-50. doi: 10.1111/jth.15156. Epub 2020 Nov 18. J Thromb Haemost. 2021. PMID: 33119197 Free PMC article. Review.
-
Prothrombotic Phenotype in COVID-19: Focus on Platelets.Int J Mol Sci. 2021 Dec 20;22(24):13638. doi: 10.3390/ijms222413638. Int J Mol Sci. 2021. PMID: 34948438 Free PMC article. Review.
Cited by
-
Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel). 2024 Jan 7;14(1):93. doi: 10.3390/life14010093. Life (Basel). 2024. PMID: 38255708 Free PMC article. Review.
-
Differential platelet activation through an interaction with spike proteins of different SARS-CoV-2 variants.J Thromb Thrombolysis. 2023 Nov;56(4):538-547. doi: 10.1007/s11239-023-02891-x. Epub 2023 Sep 22. J Thromb Thrombolysis. 2023. PMID: 37736784
-
A guide to molecular and functional investigations of platelets to bridge basic and clinical sciences.Nat Cardiovasc Res. 2022 Mar;1(3):223-237. doi: 10.1038/s44161-022-00021-z. Epub 2022 Mar 3. Nat Cardiovasc Res. 2022. PMID: 37502132 Free PMC article.
-
Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity.Cell Rep. 2023 Jun 27;42(6):112613. doi: 10.1016/j.celrep.2023.112613. Epub 2023 May 29. Cell Rep. 2023. PMID: 37302069 Free PMC article.
-
The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial.Clin Exp Med. 2023 Nov;23(7):3501-3508. doi: 10.1007/s10238-023-01101-5. Epub 2023 Jun 9. Clin Exp Med. 2023. PMID: 37294478 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
